MediPal Holdings Corporation
Stock Price Chart
2026/09/08 UpdatedPrice Trend
2026/09/08 UpdatedPrice & Trading Details
2026/09/08 UpdatedPRICE
TRADING
Analyst Recommendations 4 analysts
Updated 2026/09/01Earnings Calendar
Updated 2026/09/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/14 | ¥38.24 | ¥25.19 | -34.1% |
| 2026/02/09 | ¥50.07 | ¥74.68 | +49.2% |
| 2025/11/04 | ¥44.32 | ¥60.63 | +36.8% |
| 2025/08/05 | ¥42.51 | ¥46.17 | +8.6% |
Shareholder Composition
Updated 2026/09/01Top Mutual Funds / ETFs
Updated 2026/09/01Major Holders
Updated 2026/09/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Columbia Funds Series Trust-Columbia Overseas Value Fund
|
2.8M | +4.48% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
2.7M | -0.56% | |
|
Datum One Series Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND
|
2.0M | -4.09% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.8M | +1.30% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
1.3M | 0.00% | |
|
Fidelity Salem Street TRT-Fidelity SAI Intl Low Volatility Index Fd.
|
1.0M | +3.18% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
126 | +1.00% |
Dividend History
Updated 2026/09/06| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥34 | -46.9% |
| 2025 | ¥64 | +6.7% |
| 2024 | ¥60 | +13.2% |
| 2023 | ¥53 | +15.2% |
| 2022 | ¥46 | - |
Financial Performance
2026/09/06 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥3,290,921M | ¥3,360,008M | ¥3,558,732M | ¥3,671,328M |
| Gross Profit | ¥217,445M | ¥224,304M | ¥246,654M | ¥255,758M |
| Operating Income | ¥45,627M | ¥48,976M | ¥47,334M | ¥55,613M |
| Pretax Income | ¥57,300M | ¥70,095M | ¥74,749M | ¥76,741M |
| Net Income | ¥29,423M | ¥38,806M | ¥41,474M | ¥40,279M |
| EPS | ¥131.41 | ¥179.12 | ¥195.83 | ¥193.20 |
| Operating Margin | 1.39% | 1.46% | 1.33% | 1.51% |
| Balance Sheet | ||||
| Total Assets | ¥1,709,474M | ¥1,709,658M | ¥1,799,127M | ¥1,824,984M |
| Total Equity | ¥530,301M | ¥561,357M | ¥600,349M | ¥619,564M |
| Total Liabilities | ¥1,179,173M | ¥1,148,301M | ¥1,198,778M | ¥1,205,420M |
| Cash | ¥243,150M | ¥195,031M | ¥230,154M | ¥261,407M |
| Interest-bearing Debt | ¥30,078M | ¥0M | - | - |
| Equity Ratio | 31.02% | 32.83% | 33.37% | 33.95% |
| D/E Ratio | 0.06 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥61,216M | ¥16,146M | ¥61,843M | ¥60,559M |
| Investing CF | -¥24,343M | -¥39,494M | -¥7,817M | -¥3,363M |
| Financing CF | -¥16,471M | -¥43,541M | -¥25,248M | -¥25,947M |
| Free CF | ¥42,339M | ¥2,642M | ¥42,448M | ¥48,128M |
| Efficiency | ||||
| ROE | 5.55% | 6.91% | 6.91% | 6.50% |
| ROA | 1.72% | 2.27% | 2.31% | 2.21% |
Latest IR Information
-
Notice of Request for an Extraordinary General Meeting of Shareholders by Shareholders
We have received a request for the convocation of an extraordinary general meeting of shareholders. Four agenda items are proposed: removal of Director Shuichi Watanabe, partial amendment of the articles of incorporation, a special dividend, and a share buyback. The...
Read more -
Q1 2027 Term Financial Summary (Japan GAAP) (Consolidated)
Sales of 989,503 hundred million yen, up 4.7% YoY; quarterly net income attributable to owners of parent of 13,646 hundred million yen, up 42.3% YoY. By segment, medical pharmaceuticals wholesale is strong, but overall operating income declines to 13,386 hundred...
Read more -
[Medipal HD] Dividend Revision｜Fiscal Year Ending March 2027
Medipal HD has revised its dividend forecast for the fiscal year ending March 2027, increasing both the interim and year-end dividends by 10 yen to 44 yen each, with an expected total annual dividend of 88 yen.
Read more -
Full-year Earnings Forecast Revision ｜ Medipal Holdings July 14, 2026
Medipal Holdings Corporation revised its full-year consolidated earnings forecast for the fiscal year ending March 2027, announced on May 14, 2026. Revenue remains unchanged at 3,944,000 hundred million yen, while net profit has been upwardly revised to 43,000 hundred million...
Read more -
[Medipal Holdings] Receipt of Dividends from Consolidated Subsidiaries | July 2026
Expected receipt of dividends totaling 42,100 million yen from 8 consolidated subsidiaries. This amount will be recorded as operating income in the standalone financial statements for the fiscal year ending March 2027 and will not impact consolidated results.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,950
Rating Score: 3.25 (Based on 4 analysts)
※1=Strong Buy, 5=Strong Sell
Medipal Holdings 7459 JP - Smartkarma ↗
Company Information
About
MediPal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. The company engages in the manufacture and supply of medical drugs, medical devices, medical supplies, clinical test reagents, and medical equipment and materials; non-life insurance agency business; outsourcing of medical office administration services; research and development of preventive medicine and cutting-edge medical technologies; and construction of a medical materials database. It is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; and food processing raw materials for agriculture, fisheries, and livestock. In addition, the company offers management and marketing support for insurance pharmacies; logistics contract; veterinary medicines and feed additives; and food processing raw materials, food ingredients, food additives, and chemical product materials. It serves hospitals, clinics, pharmacies, drugstores, home centers, convenience store, supermarkets, veterinary clinics, livestock and fisheries businesses, processed food manufacturers, and other medical facilities. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to MediPal Holdings Corporation in October 2009. The company was founded in 1898 and is headquartered in Chuo, Japan.
